A blog reader forwarded this article to me. Thank you.
"Margaret Hamburg, the head of the FDA, turned up at Reuters Health Summit with a bullish assessment of both the agency's responsiveness as well as the biopharma industry's improving track record on R&D and new approvals. And she's promising that a new "breakthrough" drug program has the potential to shave three to 5 years off the development process."
Full article here.